PLA2G7 and atherosclerosis: Unfortunately, darapladib, which was discovered by GlaxoSmithKline (GSK) and is the most advanced Lp‐PLA2 inhibitor in clinical trials, missed the primary endpoints in two phase III trials in atherosclerosis patients in 2014.19, 20 Although these failures dim the future of anti‐inflammatory drug discovery for atherosclerosis, favorable results of applying Lp‐PLA2 inhibitors to diabetic macular edema (DME) and Alzheimer's disease (AD) have been consistently reported over the last few years.21, 22